COMPANY
Allinaire Therapeutics
Allinaire is developing humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies, which are currently being progressed as a potential disease-modifying treatment for PAH. From company website Source · Oct 12, 2026
NIH awards 5
- NIH award 1R44HL186831-01 FY2026: $1,498,892 awarded for that fiscal year; activity R44 (SBIR); PI HAY, DOUGLAS W.P.; recipient as written: ALLINAIRE THERAPEUTICS, LLC, CLEVELAND, OH. An anti-EMAP II monoclonal antib source ↗
- NIH award 5R44HL127873-04 FY2018: $958,776 awarded for that fiscal year; activity R44 (SBIR); PI PAWLOWSKI, CHRISTA LYNN; recipient as written: ALLINAIRE THERAPEUTICS, LLC, CLEVELAND, OH. Development of a Fully Human source ↗
- NIH award 1R41HL135945-01A1 FY2018: $281,155 awarded for that fiscal year; activity R41 (STTR); PI CLAUSS, MATTHIAS; recipient as written: ALLINAIRE THERAPEUTICS, LLC, CLEVELAND, OH. Humanized EMAP II mAb as a Novel source ↗
- NIH award 2R44HL127873-03 FY2017: $715,140 awarded for that fiscal year; activity R44 (SBIR); PI HAY, DOUGLAS W.P.; recipient as written: ALLINAIRE THERAPEUTICS, LLC, CLEVELAND, OH. Development of a Fully Humanized A source ↗
- NIH award 6R43HL127873-02 FY2015: $52,013 awarded for that fiscal year; activity R43 (SBIR); PI CLAUSS, MATTHIAS; recipient as written: ALLINAIRE THERAPEUTICS, LLC, CLEVELAND, OH. Development of a Fully Humanized Ant source ↗
Funding and NIH signals
- SEC Form D raise Raised $700K (Form D filed Apr 14, 2026). SEC Form D 0002113399-26-000001 (Apr 14, 2026)
Evidence (1 event)
- Apr 14, 2026 · SEC Form D 0002113399-26-000001
Name of Issuer: Allinaire Therapeutics Inc.; CIK: 2113399; Address: Cleveland, OH; Submission type: D; Filing date: 2026-04-14; Industry Group: Other; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 700000; Total Amount Sold: 700000; Federal exemptions: 06b
- Apr 14, 2026 · SEC Form D 0002113399-26-000001
- NIH award NIH awarded $1.5M (SBIR Phase II 1R44HL186831-01, new, notice Sep 9, 2026). NIH RePORTER 1R44HL186831-01 (Sep 9, 2026)
Evidence (1 event)
- Sep 9, 2026 · NIH RePORTER 1R44HL186831-01
Organization: ALLINAIRE THERAPEUTICS, LLC; City/State: CLEVELAND, OH; Project number: 1R44HL186831-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1498892; Administering IC: National Heart Lung and Blood Institute; Project title: An anti-EMAP II monoclonal antibody as a first-in-class treatment for Group III pulmonary hypertension patients with chronic obstructive pulmonary disease; Organization type: Domestic For-Profits
- Sep 9, 2026 · NIH RePORTER 1R44HL186831-01